Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$0.76 -1.3%	$1.11	$0.74 ▼ $1.76	$30.31M	1.09	661,224 shs	382,132 shs
AXLA Axcella Health	$0.40 -8.9%	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	6,700 shs
CRDF Cardiff Oncology	$4.07 +2.0%	$4.27	$0.94 ▼ $6.42	$181.85M	1.94	1.47 million shs	516,205 shs
FNCH Finch Therapeutics Group	$2.32 +3.6%	$2.53	$1.86 ▼ $16.74	$3.74M	0.46	38,078 shs	37,434 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	-1.91%	-3.20%	-37.55%	-19.33%	-5.56%
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	-96.27%
CRDF Cardiff Oncology	-4.55%	-8.70%	-25.97%	+167.79%	+159.09%
FNCH Finch Therapeutics Group	-2.61%	-4.68%	-14.18%	-22.76%	-83.77%

Move Your Money Before May 22 (Ad)

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	2.9098 of 5 stars	3.0	5.0	0.0	0.0	3.1	0.8	1.3
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	0.7359 of 5 stars	3.5	2.0	0.0	0.0	0.8	0.0	0.0
FNCH Finch Therapeutics Group	0.3748 of 5 stars	0.0	3.0	0.0	0.0	1.0	2.5	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	2.00	Hold	$4.00	426.32% Upside
AXLA Axcella Health	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	3.00	Buy	$10.50	157.99% Upside
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AXLA, FNCH, ACHL, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/5/2024	ACHL Achilles Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $6.00
4/5/2024	ACHL Achilles Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$8.00 ➝ $2.00
3/6/2024	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $14.00
3/1/2024	CRDF Cardiff Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $7.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CRDF Cardiff Oncology	$490K	371.12	N/A	N/A	$1.56 per share	2.61
FNCH Finch Therapeutics Group	$110K	33.96	N/A	N/A	$14.25 per share	0.16

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.74	N/A	N/A	N/A	N/A	-42.55%	-37.54%	5/8/2024 (Estimated)
AXLA Axcella Health	-$81.19M	-$19.25	N/A	∞	N/A	N/A	N/A	-259.91%	N/A
CRDF Cardiff Oncology	-$41.44M	-$0.93	N/A	N/A	N/A	-8,492.01%	-50.13%	-44.31%	5/2/2024 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$47.67	N/A	∞	N/A	N/A	-136.63%	-57.40%	5/8/2024 (Estimated)

Latest AXLA, FNCH, ACHL, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/4/2024	Q4 2023	ACHL Achilles Therapeutics	N/A	-$0.46	-$0.46	-$0.46	N/A	N/A
3/25/2024	Q4 2023	FNCH Finch Therapeutics Group	N/A	-$1.89	-$1.89	-$1.89	N/A	N/A
2/29/2024	Q4 2023	CRDF Cardiff Oncology	-$0.26	-$0.21	+$0.05	-$0.21	$0.08 million	$0.16 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	8.57	8.57
AXLA Axcella Health	N/A	0.80	0.80
CRDF Cardiff Oncology	N/A	7.41	7.41
FNCH Finch Therapeutics Group	N/A	6.33	6.33

Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
AXLA Axcella Health	65.07%
CRDF Cardiff Oncology	16.29%
FNCH Finch Therapeutics Group	21.77%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
AXLA Axcella Health	2.20%
CRDF Cardiff Oncology	6.30%
FNCH Finch Therapeutics Group	44.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	204	39.88 million	37.73 million	Not Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	Optionable
CRDF Cardiff Oncology	31	44.68 million	41.86 million	Optionable
FNCH Finch Therapeutics Group	1	1.61 million	885,000	No Data

AXLA, FNCH, ACHL, and CRDF Headlines

Source	Headline
	Finch Therapeutics Group (NASDAQ:FNCH) Shares Down 5.1% americanbankingnews.com - April 20 at 2:11 AM
	Finch Therapeutics Group (NASDAQ: FNCH) fool.com - April 14 at 2:07 AM
	Jeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Stock insidertrades.com - March 31 at 6:14 AM
	FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023 investorplace.com - March 25 at 10:03 PM
	Finch Therapeutics Group Inc (FNCH) investing.com - March 7 at 8:34 AM
	Finch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest Report benzinga.com - February 22 at 10:58 AM
	Finch Therapeutics Group Inc FNCH morningstar.com - November 5 at 2:05 PM
	Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH) markets.businessinsider.com - August 21 at 8:59 AM
	Finch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common Stock finanznachrichten.de - June 9 at 10:08 AM
	HC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy Recommendation msn.com - May 13 at 12:13 PM
	8-K: Finch Therapeutics Group, Inc. marketwatch.com - May 12 at 4:12 PM
	Finch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates finanznachrichten.de - May 10 at 10:20 AM
	Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates finance.yahoo.com - May 10 at 10:20 AM
	Finch Therapeutics Announces Executive Leadership Transitions finance.yahoo.com - April 25 at 7:24 PM
	FINCH THERAPEUTICS GROUP INC finanznachrichten.de - April 22 at 11:01 PM
	Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement finance.yahoo.com - April 18 at 5:59 PM
	Finch Therapeutics Group (FNCH) Gets a Buy from H.C. Wainwright markets.businessinsider.com - April 4 at 9:51 AM
	Finch Therapeutics Group, Inc.: Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates finanznachrichten.de - April 3 at 2:18 PM
	Looking Into Finch Therapeutics Group's Return On Capital Employed msn.com - March 25 at 5:45 PM
	Finch Therapeutics Group Full Year 2022 Earnings: Misses Expectations finance.yahoo.com - March 25 at 12:44 PM
	Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates finance.yahoo.com - March 23 at 6:49 PM
	Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months finance.yahoo.com - January 24 at 6:22 PM
	Finch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCH marketwatch.com - January 24 at 1:22 PM
	Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets finance.yahoo.com - January 24 at 8:21 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achilles Therapeutics

NASDAQ:ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Axcella Health

NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Cardiff Oncology

NASDAQ:CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Finch Therapeutics Group

NASDAQ:FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial